Business News • PR NewsWire • S*BIO Presents Positive Safety and Tolerability Results for Its Novel Oral JAK2 Inhibitor SB1518 From a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)

S*BIO Presents Positive Safety and Tolerability Results for Its Novel Oral JAK2 Inhibitor SB1518 From a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)

S*BIO Presents Positive Safety and Tolerability Results for Its Novel Oral JAK2 Inhibitor SB1518 From a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)

SINGAPORE, June 13 /PRNewswire/ -- S*BIO Pte Ltd today announced the presentation of positive safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) results for its novel oral JAK2 inhibitor, SB1518, at the 15th Congress of the European Hematology Association (EHA), June 10-13, in Ba

View More : http://www.prnewswire.com/news-releases/sbio-presents-positive-safety-and-tolerability-results-for-its-novel-oral-jak2-i...

Releted News by prnewswire

The Bridge Run 2010: a People's Party for Denmark and Sweden

Physicians Can Earn Board Certification in Bariatric Medicine

U.S. Census Bureau Daily Feature for June 13

S*BIO Presents Positive Safety and Tolerability Results for Its Novel Oral JAK2 Inhibitor SB1518 From a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)

Premier Reverse Closings Online Rate Calculator a First in the Reverse Mortgage Industry

Al-Futtaim to Grow Stronger on Willett's Customer Blueprint

iSkysoft Released DVD Creator for Both Windows and Mac